Search

Your search keyword '"Evers, B. Mark"' showing total 144 results

Search Constraints

Start Over You searched for: Author "Evers, B. Mark" Remove constraint Author: "Evers, B. Mark" Publisher american association for cancer research (aacr) Remove constraint Publisher: american association for cancer research (aacr)
144 results on '"Evers, B. Mark"'

Search Results

3. Data from Diaminobutoxy-substituted Isoflavonoid (DBI-1) Enhances the Therapeutic Efficacy of GLUT1 Inhibitor BAY-876 by Modulating Metabolic Pathways in Colon Cancer Cells

5. Supplementary Data from Potent Synergistic Effect on C-Myc–Driven Colorectal Cancers Using a Novel Indole-Substituted Quinoline with a Plk1 Inhibitor

14. Supplementary Data from Diaminobutoxy-substituted Isoflavonoid (DBI-1) Enhances the Therapeutic Efficacy of GLUT1 Inhibitor BAY-876 by Modulating Metabolic Pathways in Colon Cancer Cells

18. Supplementary Data from Potent Synergistic Effect on C-Myc–Driven Colorectal Cancers Using a Novel Indole-Substituted Quinoline with a Plk1 Inhibitor

19. Supplementary Data from Diaminobutoxy-substituted Isoflavonoid (DBI-1) Enhances the Therapeutic Efficacy of GLUT1 Inhibitor BAY-876 by Modulating Metabolic Pathways in Colon Cancer Cells

20. Supplementary Figure 3 from Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors

21. Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy

22. Supplementary Data from Ketogenesis Attenuates KLF5-Dependent Production of CXCL12 to Overcome the Immunosuppressive Tumor Microenvironment in Colorectal Cancer

24. Supplementary Data from Ketogenesis Attenuates KLF5-Dependent Production of CXCL12 to Overcome the Immunosuppressive Tumor Microenvironment in Colorectal Cancer

26. Supplementary Figure 5 from Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors

28. Supplementary Data from Ketogenesis Attenuates KLF5-Dependent Production of CXCL12 to Overcome the Immunosuppressive Tumor Microenvironment in Colorectal Cancer

29. Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy

32. Supplementary Figure 5 from Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors

34. Supplementary Figure 4 from Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors

36. Supplementary Figure 2 from Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors

37. Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy

40. Data from Ketogenesis Attenuates KLF5-Dependent Production of CXCL12 to Overcome the Immunosuppressive Tumor Microenvironment in Colorectal Cancer

41. Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy

42. Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy

43. Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy

44. Supplementary Figure 1 from Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors

45. Supplementary Figure 1 from Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors

48. Supplementary Figure 4 from Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors

49. Supplementary Table from Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy

Catalog

Books, media, physical & digital resources